Neptune Medical

Neptune Medical

At-home fertility diagnostics and non-invasive device

Overview

Neptune Medical develops devices and tests to address male infertility. Its two main products are Pro-Test, an at-home diagnostic kit that lets individuals test fertility parameters from home, and Neptune, a non-invasive device designed to improve sperm quality. Pro-Test provides a convenient way to assess fertility without clinic visits, while Neptune uses a proprietary, non-invasive method to enhance key sperm metrics and is intended for home use alongside clinical fertility treatment. The company serves both clinics (B2B) and individual consumers (B2C) and markets its products to help diagnose and treat male infertility, a factor in about half of all infertility cases. Neptune Medical differentiates itself by offering integrated, consumer-accessible diagnostics and treatment tools, backed by grant funding and participation in precision medicine programs, aiming to make diagnosis and treatment more private, accessible, and effective.

About Neptune Medical

Simplify's Rating
Why Neptune Medical is rated
C-
Rated C on Competitive Edge
Rated C on Growth Potential
Rated D+ on Differentiation

Industries

Healthcare

Consumer Goods

Company Size

1-10

Company Stage

Series D

Total Funding

$97M

Headquarters

Burlingame, California

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • Varicocele embolization boosts sperm parameters, complementing Neptune's enhancement device.
  • E-cigarette harm awareness drives Pro-Test demand for lifestyle-impacted diagnostics.
  • Innovate UK and Horizon 2020 grants validate clinical innovation for market entry.

What critics are saying

  • Varicocele embolization by University Radiology eliminates Neptune device need in 12-24 months.
  • RSC New Jersey clinics integrate evaluations, cutting Pro-Test demand in 6-18 months.
  • Clomiphene citrate adoption by urologists cannibalizes device market in 12-24 months.

What makes Neptune Medical unique

  • Pro-Test delivers at-home male fertility diagnostics for convenient sperm analysis.
  • Neptune device non-invasively enhances sperm quality via patented home-use technology.
  • Targets male infertility gap, serving B2B clinics and B2C consumers since 2018.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$97M

Above

Industry Average

Funded Over

0 Rounds

Benefits

401(k) Company Match

Company Equity

Company News

The Robot Report
Oct 4th, 2024
Robotics Investments Near $1B In August

Listen to this articleSwiss-Mile raised $22M in August 2024 for its wheeled quadruped. Fifty producers of robots and robotics enabling technologies received funding in August 2024, pulling in a total of approximately $1 billion. This figure is on par with the $1.2 billion average The Robot Report has tracked each of the previous 12 months. Investment targeted to robotics companies for the first eight months of 2024 equals about $10.86 billion. You can follow The Robot Report‘s investment section here. The largest investments in August were secured by developers of autonomous driving technologies

Business Wire
Aug 17th, 2024
Neptune Medical Announces $97M Series D Financing and Spinout of Jupiter Endovascular

Neptune Medical announces $97 million in Series D financing, along with the spinout of its Jupiter Endovascular subsidiary.

Recently Posted Jobs

Sign up to get curated job recommendations

Neptune Medical is Hiring for 10 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →